Peripheral Arterial DiseaseNCT05447052
The Biomimetic Stent and Vascular Functions Study
A study testing Bio-MIMICS 3D Stent and Innova Stent in people with Peripheral Arterial Disease, run by University Hospital, Essen at 1 site in Germany.
Trial summary
The aim of this IIT is to determine the potential improvement and impact of the BioMimics 3D Stent System in the SFA on local vascular function. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Peripheral Arterial Disease
- What is being tested?
- Bio-MIMICS 3D Stent and Innova Stent
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteGermany
- Study dates
- 26 Apr 2021to 26 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Peripheral artery disease
- Target lesions in the proximal (3 cm distal to the CFA-bifurcation) middle and distal SFA
- Clinical diagnosis of chronic, symptomatic lower limb ischemia as defined by Rutherford 2,3,4
- Planed peripheral intervention TASC A-D
- Subject must be between 18 and 85 years old
- Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12 month angiographic evaluation
Show all 12Show fewer
- Vessel diameter >/= 4.0 mm and </=7.0 mm
- Target lesion length < 140 mm (segment to be stented)
- Willing to comply with the specified follow-up evaluation
- Written informed consent prior to any study procedures
- Pretreatment with an adequately sized ballon (1:1 ration to nonstenotic vessel diameter)
- usage of Biomimics stent as described in the IFU, especially regarding stent diameters and vessel size
Who cannot join
- Bifurcational lesions of the CFA and lesions including the first 3 cm of the SFA, due to technical aspects of FMD measurement
- Requiring stent implantation in the PA
- Instent-Restenosis
- Thrombolysis within 72 Hours prior to the index procedure
- Aneurysm formations in the femoral artery or popliteal artery
- Concomitant hepatic insufficiency, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy
Show all 13Show fewer
- Unstable angina pectoris at the time of the enrollment
- Recent myocardial infarction or stroke <30 days prior to the index procedure
- Life expectancy less than 12 months
- Septicaemia at the time of enrollment
- Known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb
- Known or suspected allergies or contraindications to aspirin, clopidogrel or heparin
- Presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
University of Essen, Clinic of Cardiology and Angiology
Essen, North Rhine-Westphalia, 45147
Christos Rammos, Prof., +4920172384808, christos.rammos@uk-essen.de
Tienush Rassaf, Univ.-Prof., +492017234801, tienush.rassaf@uk-essen.de
About this study
Official title: The Biomimetic Stent and Vascular Functions Study-The MIMICS FLOW STUDY
The aim of this IIT is to determine the potential improvement and impact of the BioMimics 3D Stent System in the SFA on local vascular function.
Read the detailed description
The MIMICS FLOW Study is a single-center, single-blind, investigator-initiated, randomized parallel group trial.
The impact of a novel biomimetical stent with a helical curvature provides superior hemodynamic and biomechanical performance and advantages. Additionally, it promotes swirling blood flow, elevating wall sheer strength, which is patency-protective and might impact on vascular functions due to completely different vascular properties through altered blood flow.
The influence of the novel devices and stent-platforms with improved hemodynamic capabilities with respect to vasomotor of the vessel wall, vascular function and vascular compliance can be measured by FMD, arterial stiffness indices and vascular strain analysis.
- Conditions
- Peripheral Arterial Disease
- Being tested
- Bio-MIMICS 3D Stent, Innova Stent
- Medical subject headings
- Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bio-MIMICS 3D StentDevice
Bio-MIMICS Stent implantation
Innova StentDevice
Innova Stent implantation
| Study group | Role | What they receive |
|---|---|---|
| Bio-MIMICS Stent | Experimental | Helical shaped BioMimics 3D Stent Receives: Device: Bio-MIMICS 3D Stent |
| Innova Stent | Active comparator | Conventional: Nitinol Stent Receives: Device: Innova Stent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of flow-mediated vasodilation (FMD) of the nonstenotic segment of the proximal SFA after procedure
FMD represents the percent diameter gain as calculated based on preischemia and postischemia diameter measurements of the femoral artery.
Measured: 1 month
Change of flow-mediated vasodilation (FMD) of the nonstenotic segment of the proximal SFA after procedure
FMD represents the percent diameter gain as calculated based on preischemia and postischemia diameter measurements of the femoral artery.
Measured: 12 months
Secondary outcomes (12)
Changes in pulse wave velocity
Changes in cardiovascular function measured by pulse wave velocity in m/s
Measured: Baseline, followed at 1 and 12 months
Changes in augmentation index
Changes in cardiovascular function measured by augmentation index in %
Measured: Baseline, followed at 1 and 12 months
Changes in vascular strain
Changes in cardiovascular function measured by vascular strain in %
Measured: Baseline, followed at 1 and 12 months
Changes in peripheral perfusion determined by ABI (ankle brachial index)
ABI measurements are conducted using a Doppler probe on tibial and anterior artery locations. The highest value will be used for calculation and divided by the highest systolic brachial Doppler pressure
Measured: Baseline, followed at 1 and 12 months
Primary patency (PP) of target lesion
Primary patency determined by PVR measurement with ultrasound
Measured: Baseline, followed at 1 and 12 months
Changes in clinical symptoms
Clinical symptoms of patients determined by Walking impairment questionaire (WIQ)
Measured: Baseline, followed at 1 and 12 months
Changes in six-minute walk test
Six-minute walk test determined by pain-free walking distance in m
Measured: Baseline, followed at 1 and 12 months
Freedom from Target Lesion Revascularization
Freedom from Target Lesion Revascularization (FTLR)
Measured: Baseline, followed at 1 and 12 months
Number of participants with treatment-related adverse events
Number of participants with treatment-related adverse events as assessed by SDWS
Measured: Baseline, followed at 1 and 12 months
Changes of inflammatory profile measured by hs-CRP in mg/dl
Blood samples are collected at the below mentioned time points
Measured: Baseline, followed at 1 and 12 months
Changes of inflammatory profile measured by oxLDL in µg/l
Blood samples are collected at the below mentioned time points
Measured: Baseline, followed at 1 and 12 months
Changes of inflammatory profile measured by Interleukin-6 in pg/ml
Blood samples are collected at the below mentioned time points
Measured: Baseline, followed at 1 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2022
- Study start26 Apr 2021
- Primary completion26 Apr 2024 (estimated)
- Study completion26 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Essen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chistos Rammos, University Hospital, Essen
- Investigators
- Christos Rammos, Professor, Principal investigator, University Hospital, Essen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05447052
- Sponsor's protocol ID
- The MIMICS FLOW STUDY
- Status last verified
- Dec 2023
- First submitted
- 2 Jun 2022
- Last updated
- 5 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Biomimetic Stent and Vascular Functions Study-The MIMICS FLOW STUDY
- ClinicalTrials.gov ID
- NCT05447052
- Acronym / sponsor ID
- The MIMICS FLOW STUDY
- Conditions
- Peripheral Arterial Disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- University Hospital, EssenUniversity, hospital or other
- Study start
- 26 Apr 2021 (actual)
- Primary completion
- 26 Apr 2024 (estimated)
- Study completion
- 26 Apr 2025 (estimated)
- First posted
- 7 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this IIT is to determine the potential improvement and impact of the BioMimics 3D Stent System in the SFA on local vascular function.
Detailed description
The MIMICS FLOW Study is a single-center, single-blind, investigator-initiated, randomized parallel group trial.
The impact of a novel biomimetical stent with a helical curvature provides superior hemodynamic and biomechanical performance and advantages. Additionally, it promotes swirling blood flow, elevating wall sheer strength, which is patency-protective and might impact on vascular functions due to completely different vascular properties through altered blood flow.
The influence of the novel devices and stent-platforms with improved hemodynamic capabilities with respect to vasomotor of the vessel wall, vascular function and vascular compliance can be measured by FMD, arterial stiffness indices and vascular strain analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bio-MIMICS Stent | Experimental | Device: Bio-MIMICS 3D StentHelical shaped BioMimics 3D Stent |
| Innova Stent | Active comparator | Device: Innova StentConventional: Nitinol Stent |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Peripheral artery disease
- Target lesions in the proximal (3 cm distal to the CFA-bifurcation) middle and distal SFA
- Clinical diagnosis of chronic, symptomatic lower limb ischemia as defined by Rutherford 2,3,4
- Planed peripheral intervention TASC A-D
- Subject must be between 18 and 85 years old
Key exclusion criteria (13 listed)
- Bifurcational lesions of the CFA and lesions including the first 3 cm of the SFA, due to technical aspects of FMD measurement
- Requiring stent implantation in the PA
- Instent-Restenosis
- Thrombolysis within 72 Hours prior to the index procedure
- Aneurysm formations in the femoral artery or popliteal artery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bio-MIMICS 3D StentBio-MIMICS Stent implantation | Device | Bio-MIMICS Stent |
| Innova StentInnova Stent implantation | Device | Innova Stent |
Primary outcome
Change of flow-mediated vasodilation (FMD) of the nonstenotic segment of the proximal SFA after procedure
Time frame: 1 month
FMD represents the percent diameter gain as calculated based on preischemia and postischemia diameter measurements of the femoral artery.
Change of flow-mediated vasodilation (FMD) of the nonstenotic segment of the proximal SFA after procedure
Time frame: 12 months
FMD represents the percent diameter gain as calculated based on preischemia and postischemia diameter measurements of the femoral artery.
12 secondary outcomes
Changes in pulse wave velocity
Time frame: Baseline, followed at 1 and 12 months
Changes in augmentation index
Time frame: Baseline, followed at 1 and 12 months
Changes in vascular strain
Time frame: Baseline, followed at 1 and 12 months
Changes in peripheral perfusion determined by ABI (ankle brachial index)
Time frame: Baseline, followed at 1 and 12 months
Primary patency (PP) of target lesion
Time frame: Baseline, followed at 1 and 12 months
Changes in clinical symptoms
Time frame: Baseline, followed at 1 and 12 months
Changes in six-minute walk test
Time frame: Baseline, followed at 1 and 12 months
Freedom from Target Lesion Revascularization
Time frame: Baseline, followed at 1 and 12 months
Number of participants with treatment-related adverse events
Time frame: Baseline, followed at 1 and 12 months
Changes of inflammatory profile measured by hs-CRP in mg/dl
Time frame: Baseline, followed at 1 and 12 months
Changes of inflammatory profile measured by oxLDL in µg/l
Time frame: Baseline, followed at 1 and 12 months
Changes of inflammatory profile measured by Interleukin-6 in pg/ml
Time frame: Baseline, followed at 1 and 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2023.
Related trials for Peripheral Arterial Disease
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
Peripheral Vascular Disease, Peripheral Arterial Disease
Active, not recruiting
SELUTION4SFA Trial
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
RecruitingPhase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Peripheral Arterial Disease
Recruiting
REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center
Peripheral Arterial Disease
Not yet recruitingPhase 2
REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial
Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christos Rammos, Professor principal investigator
University Hospital, Essen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bio-MIMICS 3D Stent and Innova Stent in people with Peripheral Arterial Disease, run by University Hospital, Essen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christos Rammos, Professor (0201-723-84808, christos.rammos@uk-essen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of flow-mediated vasodilation (FMD) of the nonstenotic segment of the proximal SFA after procedure (time frame: 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2023.